期刊文献+

1例多发性骨髓瘤患者合并静脉血栓栓塞的药学监护

Pharmaceutical Care of a Multiple Myeloma Patient with Venous Thromboembolism
下载PDF
导出
摘要 目的探讨临床药师在多发性骨髓瘤患者治疗团队中的作用。方法回顾分析1例多发性骨髓瘤患者历次诊疗用药情况及静脉彩超结果,分析患者血栓形成的原因及历次抗凝药物的使用。结果该例多发性骨髓瘤患者左腿胫后静脉血栓形成与沙利度胺及地塞米松联合使用有密切关系,临床药师为患者进行了后续治疗方案的推荐。结论临床药师能够在治疗团队中提供科学、有效的参考依据,协同临床医生制定药物治疗方案,提供药学监护。 Objective To discuss the role of clinical pharmacists in multiple myeloma patients’ therapeutic teams. Methods Clinical pharmacist retrospected each therapeutic scheme and the venous ultrasound results of the patient, and analysed the factors of thrombosis and anticoagulant therapy for drug use of this patient. Results The combined use of thalidomide and dexamethasone was closely related to deep vein thrombosis of the patient. Clinical pharmacist recommended a follow-up treatment prescription for the patient. Conclusions Clinical pharmacists can provide scientific and effective reference for the treatment team, and help doctors formulate drug treatment prescription, and provide pharmaceutical care.
作者 刘艳秋 宋琳婧 古曦 王丽 游丽娜 LIU Yanqiu;SONG Linjing;GU Xi;WANG Li;YOU Lina(Yan’ An Hospital of Kunming City / Yan’ an Affiliated Hospital of Kunming Medical College, Kunming, Yunnan, 650051, China)
出处 《肿瘤药学》 CAS 2018年第2期288-291,共4页 Anti-Tumor Pharmacy
关键词 多发性骨髓瘤 静脉血栓 沙利度胺 Multiple myeloma Venous thromboembolism Thalidomide
  • 相关文献

参考文献5

二级参考文献61

  • 1赵永强.我国静脉血栓栓塞症的研究现状[J].中华内科杂志,2005,44(2):83-84. 被引量:39
  • 2Singh A,Gajra A.Thromboembolism with immunomodulatory agents in the treatment of multiple myeloma[J].Cardiovasc Hematol Agents Med Chem,2011,9 (1):7-13.
  • 3Kristinsson SY,Pfeiffer RM,Bjorkholm M,et al.Arterial and venous thrombosis in monoclonal gammopathy ofundetermined significance and multiple myeloma:a population-based study[J].Blood,2010,115 (24):4991-4998.
  • 4Dunkley S,Gaudry L.Thalidomide causes platelet activation,which can beabrogated by aspirin[J].J Thromb Hemost,2007,5(6):1323-1325.
  • 5Abdullah WZ,Roshan TM,Hussin A,et al.Increased PAC-1 expression among patients with multiple myeloma on concurrent thalidomide and warfarin[J].Blood Coagul Fibrinolysis,2013,24(8):893-895.
  • 6Robak M,Trelinski J,Chojnowski K.Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma[J].Med Oncol,2012,29 (5):3574-3580.
  • 7Pal R,Monaghan SA,Hassett AC,et al.Immunomodulatory derivatives induce PU.1 down-regulation,myeloid maturation arrest,and neutropenia[J].Blood,2010,115(3):605-614.
  • 8Faraday N,Schunke K,Saleem S,et al.Cathepsin G-dependent modulation of platelet thrombus formation in vivo by blood neutrophils[J].PLoSOne,2013,8(8):e71447.
  • 9Gale AJ,Rozenshteyn D.Cathepsin G,a leukocyte protease,activates coagulation factor Ⅷ[J].Thromb Hemost,2008,99(1):44-51.
  • 10Rosovsky R,Hong F,Tocco D,et al.Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone:an observationalstudy[J].BrJ Hematol,2013,160(3):351-358.

共引文献529

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部